,51 In September 2024, the Oncologic Drugs Advisory Committee voted against the use of checkpoint inhibitors in HER2-negative gastric/GEJ adenocarcinoma with PD-L1 expression less than 1 based on pooled analysis done by the FDA showing lack of benefit in this patient population.52 Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.